You are here:


AOP Orphan Contact

AOP Orphan worldwide

Wilhelminenstraße 91/IIf
1160 Vienna, Austria
office(at)aoporphan.com

Cooperation Opportunities


Using the filter below you can find products potentially available for out-licensing in specific countries, including current regulatory status. You are welcome to express your interest by sending a message to our dedicated team at partnering(at)aoporphan.com.

Austria
Miltefosine optical solution
Regulatory Status: Phase I
Belgium
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Miltefosine optical solution
Regulatory Status: Phase I
Bulgaria
Miltefosine optical solution
Regulatory Status: Phase I
Croatia
Miltefosine optical solution
Regulatory Status: Phase I
Cyprus
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Tetrabenazine 25 mg tablet
Regulatory Status: Dosier available
Miltefosine optical solution
Regulatory Status: Phase I
Czech Republic
Miltefosine optical solution
Regulatory Status: Phase I
Denmark
Miltefosine optical solution
Regulatory Status: Phase I
Estonia
Miltefosine optical solution
Regulatory Status: Phase I
Finland
Miltefosine optical solution
Regulatory Status: Phase I
France
Miltefosine optical solution
Regulatory Status: Phase I
Germany
Miltefosine optical solution
Regulatory Status: Phase I
Greece
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Tetrabenazine 25 mg tablet
Regulatory Status: approved
Miltefosine optical solution
Regulatory Status: Phase I
Hungary
Miltefosine optical solution
Regulatory Status: Phase I
Ireland
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Tetrabenazine 25 mg tablet
Regulatory Status: approved
Miltefosine optical solution
Regulatory Status: Phase I
Italy
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Tetrabenazine 25 mg tablet
Regulatory Status: approved
Miltefosine optical solution
Regulatory Status: Phase I
Latvia
Miltefosine optical solution
Regulatory Status: Phase I
Lithuania
Miltefosine optical solution
Regulatory Status: Phase I
Luxembourg
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Tetrabenazine 25 mg tablet
Regulatory Status: Dosier available
Miltefosine optical solution
Regulatory Status: Phase I
Malta
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Miltefosine optical solution
Regulatory Status: Phase I
Netherlands
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Miltefosine optical solution
Regulatory Status: Phase I
Poland
Miltefosine optical solution
Regulatory Status: Phase I
Portugal
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Miltefosine optical solution
Regulatory Status: Phase I
Romania
Miltefosine optical solution
Regulatory Status: Phase I
Slovakia
Miltefosine optical solution
Regulatory Status: Phase I
Slovenia
Miltefosine optical solution
Regulatory Status: Phase I
Spain
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Tetrabenazine 25 mg tablet
Regulatory Status: approved
Miltefosine optical solution
Regulatory Status: Phase I
Sweden
Miltefosine optical solution
Regulatory Status: Phase I
United Kingdom
Miltefosine optical solution
Regulatory Status: Phase I
Bosnia-Hercegovina
Miltefosine optical solution
Regulatory Status: Phase I
Macedonia
Miltefosine optical solution
Regulatory Status: Phase I
Norway
Miltefosine optical solution
Regulatory Status: Phase I
Serbia
Miltefosine optical solution
Regulatory Status: Phase I
Switzerland
Miltefosine optical solution
Regulatory Status: Phase I
Canada
Landiolol 20 mg / 2 ml concentrate
Regulatory Status: Phase III
Landiolol 600 mg lyophilisate
Regulatory Status: Phase III
Landiolol 300 mg lyophilisate
Regulatory Status: Phase III
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Miltefosine optical solution
Regulatory Status: Phase I
Mexico
Landiolol 20 mg / 2 ml concentrate
Regulatory Status: Phase III
Landiolol 600 mg lyophilisate
Regulatory Status: Phase III
Landiolol 300 mg lyophilisate
Regulatory Status: Phase III
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Miltefosine optical solution
Regulatory Status: Phase I
USA
Landiolol 20 mg / 2 ml concentrate
Regulatory Status: Phase III
Landiolol 600 mg lyophilisate
Regulatory Status: Phase III
Landiolol 300 mg lyophilisate
Regulatory Status: Phase III
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Tetrabenazine 25 mg tablet
Regulatory Status: Dosier available
Miltefosine optical solution
Regulatory Status: Phase I
Kazakhstan
Landiolol 20 mg / 2 ml concentrate
Regulatory Status: Phase III
Landiolol 600 mg lyophilisate
Regulatory Status: Phase III
Landiolol 300 mg lyophilisate
Regulatory Status: Phase III
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: approved
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Tetrabenazine 25 mg tablet
Regulatory Status: approved
Miltefosine optical solution
Regulatory Status: Phase I
Russia
Landiolol 20 mg / 2 ml concentrate
Regulatory Status: Phase III
Landiolol 600 mg lyophilisate
Regulatory Status: Phase III
Landiolol 300 mg lyophilisate
Regulatory Status: Phase III
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Miltefosine optical solution
Regulatory Status: Phase I
Ukraine
Landiolol 20 mg / 2 ml concentrate
Regulatory Status: Phase III
Landiolol 600 mg lyophilisate
Regulatory Status: Phase III
Landiolol 300 mg lyophilisate
Regulatory Status: Phase III
Anagrelide 2,0 mg retard tablet
Regulatory Status: Dosier available
Anagrelide 0,5 mg capsule
Regulatory Status: Dosier available
Nabilone 1 mg capsule
Regulatory Status: Dosier available
Nabilone 0,25 mg capsule
Regulatory Status: Phase III
Tetrabenazine 25 mg tablet
Regulatory Status: approved
Miltefosine optical solution
Regulatory Status: Phase I